Investors / United States / Epidarex
Epidarex
Venture capital · Bethesda, MD, United States · North America
Epidarex is a transatlantic venture capital firm that invests in early-stage life science and health technology companies in emerging research hubs in the UK and US. It often partners with universities and research institutions to found spin-out companies, providing seed or Series A capital.
Invests inHealthcare & Biotech
In its own wordslife sciencesbiotechnologypharmaceuticalsmedical deviceshealth techuniversity spin-outs
Your fit with Epidarex
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsEpidarex lists 21 checked portfolio companies on its own site and is named in 4 funding rounds, 1 of them as lead. Its most frequent entry is Series A, 50% of the companies with a known first round. Its largest themes are Healthcare & Biotech (96%) and Robotics & Hardware (5%). 39% of its companies are based in United Kingdom. It invests most often alongside BioGeneration Ventures, Santé Ventures and Broadview Ventures.
Counts come from funding rounds that name Epidarex, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Epidarex's whole history. Rounds on record name 4 companies; its own site lists 21. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 50% |
| Series B | 50% |
| Growth | 0% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 1 | 1 |
| '26 | 3 | 0 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 53th | 21 companies |
| Recent activity | 76th | 3 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 76th | 10% of companies confirmed by a round |
| Sector focus | 97th | 96% in its largest sector |
| Reach | 84th | 6 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| BioGeneration Ventures | 3 |
| Santé Ventures | 3 |
| Broadview Ventures | 2 |
| Novartis Venture Fund | 2 |
| Sofinnova Partners | 2 |
| 3B Future Health Fund | 1 |
| ALSA Ventures | 1 |
| Advent Life Sciences | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers21100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 96% | 15% |
| Robotics & Hardware | 5% | 1% |
Co-investor network
who it backs companies with, and who they back togetherAll co-investors or Compare portfolios with BioGeneration Ventures
Compare Epidarex head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Epidarex| Date | Company | Stage |
|---|---|---|
| 6 Oct 2026 | Series A | |
| 5 Aug 2026 | Series B | |
| 16 Jul 2026 | Series B | |
| 27 May 2025 | Series A Led |
Round details for Epidarex
Amounts, full round histories and every co-investor in Epidarex's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
21 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Apellis develops life-changing medicines for patients with debilitating diseases | Healthcare & Biotech | Portfolio page | ||
| Clyde Biosciences enables earlier detection of cardiovascular risk, empowering pharmaceutical and biotech teams to make smarter decisions for clinical translation. | Healthcare & Biotech | Portfolio page | ||
| CurifyLabs develops and provides automated compounding systems for pharmacies to create personalized medicines | Healthcare & BiotechRobotics & Hardware | May 2025Series A | Funding round | |
| The company develops innovative cyclic peptide and small molecule drugs to treat diseases such as cancer, immunology and inflammation. | Healthcare & Biotech | Portfolio page | ||
| Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. | Healthcare & Biotech | Portfolio page | ||
| Epsilogen is a company that discovers and develops immunoglobulin IgE, IgA and IgG-based therapeutics for the treatment of cancer | Healthcare & Biotech | Portfolio page | ||
| Harness Therapeutics develops disease-modifying therapies for neurodegenerative diseases | Healthcare & Biotech | Portfolio page | ||
| Kodikaz Therapeutics develops targeted therapeutic products using its Zip-Code Technology platform for cell and gene therapy applications. | Healthcare & Biotech | Portfolio page | ||
| Lario Therapeutics are developing first-in-class precision medicines as disease modifying treatments for severe neurological disorders including epileptic conditions and Parkinson’s disease. | Healthcare & Biotech | Portfolio page | ||
| Leucid Bio develops next generation CAR-T therapies to improve treatment outcomes for patients with refractory cancers | Healthcare & Biotech | Portfolio page | ||
| Libra Therapeutics is advancing new therapeutics to improve lysosomal function with the potential to halt neurodegeneration in various diseases. | Healthcare & Biotech | Portfolio page | ||
| Lunac Therapeutics is developing anticoagulant therapies for the treatment and prevention of life-threatening thrombotic events | Healthcare & Biotech | Portfolio page | ||
| Macomics develops therapies that direct macrophages to degrade large protein complexes that drive disease in tissue and circulation. | Healthcare & Biotech | Portfolio page | ||
| Mironid is a clinical stage biopharmaceutical company developing novel small-molecule therapeutics that directly target the central signalling mechanism that drives ADPKD. | Healthcare & Biotech | Aug 2026Series B | Page + round | |
| Rezera develops oral NLRP3 inhibitors for chronic inflammation | Healthcare & Biotech | Portfolio page | ||
| Nyra Medical is redefining transcatheter repair for functional mitral regurgitation with a single-leaflet solution | Healthcare & Biotech | Portfolio page | ||
| RapidPulse Inc is involved in clinical trials, including a pivotal ischemic stroke study. | Healthcare & Biotech | Jul 2026Series B | Page + round | |
| RougeTx is developing small-molecule therapies to restore vascular stability in diseases driven by pericyte dysfunction | Healthcare & Biotech | Oct 2026Series A | Funding round | |
| Ryme Medical is developing a catheter-based therapy to reduce symptoms and improve long-term outcomes in patients with Chronic Obstructive Pulmonary Disease (COPD). | Healthcare & Biotech | Portfolio page | ||
| Theolytics is developing systemically deliverable immunotherapies based on oncolytic adenoviruses to target solid tumours. | Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- epidarex.com
- Last read
- 5 Nov 2026
- Watching since
- 6 Nov 2026
- Rounds since
- 27 May 2025
- Companies checked
- 21
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Epidarex's profile as data
Pull Epidarex's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/epidarex.com
# also
GET /v1/firms/epidarex.com/portfolio
GET /v1/firms/epidarex.com/coinvestors
GET /v1/firms/epidarex.com/news